Carlyle Group will purchase a 20% stake in Indian billionaire Ajay Piramal’s pharmaceutical business, according to an exchange filing.
The private equity fund will pay $490 million for the holding, valuing the business at an enterprise value of $2.7 billion. In addition to helping expand capacity of the pharmaceutical operations, the Piramal group will use the money to repay some of parent Piramal Enterprises Ltd.’s debt, the filing said.
“This infusion of funds will further strengthen our balance sheet and provide us with a war chest for the next phase of our strategy,” Ajay Piramal, chairman of Piramal Enterprises, said in the filing.
In May, Carlyle agreed to buy up to 74% of SeQuent Scientific, the largest pure-play animal healthcare company in India.
Source: Bloomberg
Can’t stop reading? Read more
TDR Capital and I Squared explore $15bn Aggreko IPO and stake sale options
TDR Capital and I Squared explore $15bn Aggreko IPO and stake sale options TDR Capital and I...
KKR, Silver Lake, and General Atlantic eye exits as Reliance Jio prepares $4bn IPO
KKR, Silver Lake, and General Atlantic eye exits as Reliance Jio prepares $4bn IPO KKR, Silver...
Apollo partners with NYSE owner Intercontinental Exchange on private credit data venture
Apollo partners with NYSE owner Intercontinental Exchange on private credit data venture Apollo...